Dermatologic adverse events to chemotherapeutic agents, Part 1: cytotoxic agents, epidermal growth factor inhibitors, multikinase inhibitors, and proteasome inhibitors

被引:12
|
作者
Kyllo, Rachel L. [1 ]
Anadkat, Milan J. [1 ]
机构
[1] Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA
关键词
SQUAMOUS-CELL CARCINOMA; CUTANEOUS LUPUS-ERYTHEMATOSUS; TYROSINE KINASE INHIBITOR; COLORECTAL-CANCER PATIENTS; FACTOR RECEPTOR INHIBITORS; CHRONIC MYELOID-LEUKEMIA; HAND-FOOT-SYNDROME; ORAL MUCOSITIS; RADIATION RECALL; BORTEZOMIB TREATMENT;
D O I
10.12788/j.sder.0060
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Dermatologic toxicities have profound effects on patients receiving chemotherapy for cancer treatment. Cytotoxic chemotherapies are associated with a number of nonspecific dermatologic adverse events including alopecia, mucositis, and onychodystrophy. Targeted therapies including epidermal growth factor inhibitors, multikinase inhibitors, and proteasome inhibitors are associated with different skin reactions that are class-specific. In Part 1 of this review, we examine the presentations of the most common dermatologic adverse events associated with the above drugs and discuss the strategies used for their prevention and treatment.
引用
收藏
页码:28 / 39
页数:12
相关论文
共 50 条
  • [1] Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab
    Choi, Jennifer Nam
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2014, 33 (01) : 40 - 48
  • [2] Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors
    Wu, Peggy A.
    Balagula, Yevgeniy
    Lacouture, Mario E.
    Anadkat, Milan J.
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (04) : 343 - 351
  • [3] Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents
    Visentin, Michele
    Biason, Paola
    Toffoli, Giuseppe
    PHARMACOLOGY & THERAPEUTICS, 2010, 128 (01) : 82 - 90
  • [4] Proteasome inhibitors as anticancer agents
    Gazzaroli, Giorgia
    Angeli, Andrea
    Giacomini, Arianna
    Ronca, Roberto
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2023, 33 (11) : 775 - 796
  • [5] Proteasome inhibitors as therapeutic agents
    Adams, J
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (01) : 45 - 57
  • [6] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents
    Fortunato Ciardiello
    Drugs, 2000, 60 : 25 - 32
  • [7] Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
    Ciardiello, F
    DRUGS, 2000, 60 (Suppl 1) : 25 - 32
  • [8] INHIBITORS OF UREASE AS CHEMOTHERAPEUTIC-AGENTS
    ROSENSTEIN, IJM
    HAMILTONMILLER, JMT
    CRC CRITICAL REVIEWS IN MICROBIOLOGY, 1984, 11 (01): : 1 - 12
  • [9] Managing dermatologic toxicities of epidermal growth factor receptor inhibitors
    Chou, Lillian S.
    Garey, Jody
    Oishi, Karen
    Kim, Edward
    CLINICAL LUNG CANCER, 2006, 8 : S15 - S22
  • [10] Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
    Chanprapaph, K.
    Vachiramon, V.
    Rattanakaemakorn, P.
    DERMATOLOGY RESEARCH AND PRACTICE, 2014, 2014